IMPORTANCE Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder with limited epidemiologic and clinicopathologic data. Little information is available on long-term outcomes, comorbidities, and treatment efficacy.
Acantholysis and focal acantholytic dyskeratosis within the epidermis have been described, features which have been suggested to be helpful in distinguishing PRP from psoriasis. 7 Based on the age at onset, the disease course, and associated underlying conditions, Griffiths 8 Pityriasis rubra pilaris is considered a rare disease, with an estimated incidence of 1 in 400 000, yet the precise prevalence is unknown. 8 Because of its low prevalence, relatively little has been reported about epidemiologic trends, clinicopathologic features, and disease course. This multinational study of 100 patients seeks to describe epidemiologic, clinicopathologic, diagnostic, and therapeutic features, as well as patient impressions, of adult and pediatric PRP.
Methods

Study Design and Patient Recruitment
Prospective patients were recruited through 2 PRP support group websites (http://www.prp-support.org/wp/ and http: //prpalliance.com). Patients requesting enrollment received, and completed, a Thomas Jefferson University institutional review board-approved informed consent form, together with a release of medical records forms, and the survey tool. Patients were not compensated for their participation.
Study Procedures
The patient survey consisted of 7 sections: (1) diagnosing and/or identifying information on treating physician(s), (2) demographic data, (3) description of symptoms and signs, (4) diagnostic procedures, (5) treatments, (6) medical history, and (7) disease course. Regarding treatments, patients were queried about the utility and perceived helpfulness of each modality. Using the informed consent and authorization to release medical records, study personnel obtained original clinical notes, pathology reports, and photographs.
The first 100 patients requesting enrollment, who selfidentified as having a diagnosis of PRP, were included in the study. Two study dermatologists (H.J.C. and M.S.K.) systematically reviewed each patient's medical record, independently, using predetermined criteria to assess the level of diagnostic certainty ( Table 1) .
Questionable diagnoses were discussed jointly, applying these same criteria, until a consensus was reached. These levels of diagnostic certainty, from 1 to 4, enabled subgroup data analysis, thus minimizing confounding bias.
Key Points
Question: What is the typical presentation and outcome of pityriasis rubra pilaris (PRP)?
Findings: In this case series study of 100 patients with PRP, we found that only a quarter of patients were correctly diagnosed at initial presentation, and most patients required more than 2 biopsies before a final diagnosis was made. Patients rated topical emollients, corticosteroids, and salicylic acid along with oral retinoids, methotrexate, and tumor necrosis factor inhibitors as most helpful.
Meaning: Pityriasis rubra pilaris remains a challenging diagnosis. 
Results
Epidemiologic Characteristics of the Cohort
Of the 100 enrolled patients with the putative diagnosis of PRP, 50 were categorized as level 1; 15 as level 2; 30 as level 3; and 5 as level 4, respectively. At the time of enrollment, patients of this cohort of 100 were a mean age of 57 years (range, 5-87 years; median, 61 years); 46% were female. The self-identified ethnic distribution was 93% white, 4% black, 1% Arabic, and 1% Hebrew. Twelve countries (United States, Canada, The Netherlands, Germany, France, Sweden, Denmark, Switzerland, United Kingdom, Dubai, Australia, and New Zealand) were represented in the cohort. The demographics are summarized in eTable 1 in the Supplement.
Level 1 patients were an average of 59 years of age (range, 5-84 years; median, 65 years) at enrollment. This subgroup was 56% female. The average age at symptom onset in level 1 adult cases (>19 years of age) was 57 years (range, 25 to 80 years; median, 60 years). In pediatric cases (≤19 years of age) the onset was at 7 years of age (range, 2-13 years; median, 4 years). Bimodal peaks in the age at the onset of symptoms were noted in the entire study cohort during the first and second (12% of cases) and again in the sixth and seventh decades (60%) of life ( Figure) . Similar distribution was also observed in the level 1 patients (6% and 52%, respectively).
Diagnostic Features
Only 13 level 1 patients (26%) reported being correctly diagnosed as having PRP on initial presentation. The next most common initial diagnoses reported were psoriasis, contact dermatitis, and eczema and/or spongiotic dermatitis, which accounted for 42% of level 1 initial diagnoses ( Table 2 ). The mean time to obtain the correct diagnosis was 29 months from the initial presentation (range, 0.25-288 months; median, 2 months). Twenty-seven patients (54%) reported undergoing 2 or more biopsies (mean, 2; range, 0-7 biopsies) to establish the diagnosis of PRP. The mean age at the time of diagnosis in level 1 adult cases was 58 years (range, 29-80 years; median, 60 years). In pediatric cases it was 16 years (range, 2-37 years; median, 4 years).
The spectrum of signs and symptoms in level 1 patients was broad. Forty-five patients (90%) reported widespread erythematous plaques, 10 (20%) reported prominent erythema on the extensor surfaces of the elbows and knees, and 14 (28%) reported associated hyperkeratosis, skin thickening, or tightening. Thirty-nine (78%) noted palmarplantar hyperkeratosis, thickening, or tightening. Skin flaking or ichthyosis was reported by 45 patients (90%). The presence of perifollicular erythema and scales was reported by 38 individuals (76%). Alopecia was noted in 35 patients (70%). Twelve (24%) indicated associated eczematous changes. Nail involvement, ranging from thickening and discoloration to complete sloughing of the nails, was described by 36 patients (72%). Pruritus was noted by 40 patients (80%), yet a burning sensation of the skin was noted only by 25 patients (50%).
In level 1 adult and pediatric patients, 32 (64%) and 4 (8%) indicated persistent, ongoing symptoms of PRP, at the time of the study, respectively. Thirteen of level 1 adult patients (26%) and 1 pediatric patient (2%) reported remission at the time of study enrollment (see eTable 1 in the Supplement). The former patients (adult plus pediatric) noted that their symptoms had been present for an average of 58 months (range, 1-300 months; median, 30 months). Twenty-four of these individuals (48%) indicated that they were diagnosed as having PRP type 1; 2 (4%) indicated type 2; 4 (8%), type 3; and none as types Note bimodal distribution with peaks in the first and the sixth to seventh decades. a Some patients indicated 1 or more initial diagnoses; as such, columns contain more diagnoses than the cohort size, and percentages sum to greater than 100%. b These patients received a diagnosis of pityriasis rubra pilaris at initial presentation. 
Histopathologic Findings
Representative biopsies of 69 patients (69%) were obtained. Most level 1 patients (54%) reported having had 2 or more biopsies mean, 2; range, 0-7 biopsies). Characteristic epidermal features noted were acanthosis, hyperkeratosis, as well as orthokeratosis and parakeratosis in a "checkerboard pattern" (see eTable 2 in the Supplement). The dermis most commonly showed alterations (eg, dilation) in vasculature with primarily perivascular, lymphohistiocytic infiltrates. In the study cohort of 100 patients, PRP was the most common clinical differential diagnosis on the histopathology referral forms available for review (n = 31); the next most common were psoriasis (n = 16), cutaneous T-cell lymphoma (n = 9), eczema (n = 6), and drug reaction (n = 4) (see eTable 3 in the Supplement).
Comorbidities
The available medical history revealed that 31 patients of level 1 of diagnostic certainty (62%) had 1 or more significant comorbidity; these are detailed in Table 3 . The 3 most common disorders were hypothyroidism in 10 (20%), dyslipidemias in 9 (18%), and other cutaneous comorbidities in 7 (14%).
Thirteen (26%) patients indicated that they experienced depression "always" or "often"; 15 (30%) experienced symptoms "sometimes"; and 10 (20%) "rarely" (eTable 4 in the Supplement).
Only 6 (12%) indicated that they are "never" depressed. When asked what percentage of their depression they believe is secondary to PRP, nearly half (46%) said that it was primarily (51%-100%) related to their skin disorder.
Treatment History
Ninety-six patients of the total cohort of 100 (96%) indicated that they received either a topical or oral therapy during the course of their disease; 49 level 1 patients (98%) used some form of therapy ( Table 4) . The 3 most commonly reported topical therapies were emollients (90%), corticosteroids (76%), and urea (68%). Among these, emollients (76%), corticosteroids (50%), and salicylic acid (45%) were perceived most helpful by the patients.
The most commonly used systemic therapies were retinoids (64%), methotrexate (42%), and light therapy (26%). Systemic modalities rated as most helpful were retinoids (59%), methotrexate (52%), and tumor necrosis factor (TNF) inhibitors (40%). Interestingly, although light therapy was one of the most common systemic therapies used, only 1 in 13 patients found it helpful. Few patients were prescribed TNF inhibitors (20%), but these were considered most helpful by 4 of level 1 patients (40%), and of the 19 patients (across all levels of diagnostic certainty) who reported use of TNF inhibitors, 5 (26%) believed them to be helpful.
Discussion
This study presents epidemiologic, clinicopathologic as well as diagnostic and treatment challenges in 100 patients with a self-reported diagnosis of PRP. As such, to our knowledge, this is the largest reported cohort of patients with PRP. In addition, this is also the first study to provide patient perspectives regarding the diagnostic and treatment course of PRP. The evidence supporting the putative diagnosis of PRP was subsequently reviewed to subcategorize the patients to 4 levels of diagnostic certainty. As such, cases belonging to levels 1 to 3 represent a spectrum of phenotypes that dermatologists around the world, to the best of their knowledge, are diagnosing and treating as PRP. Interestingly, although level 4 patients were deemed to have a diagnosis other than PRP, each one of these patients were, at one point, suspected of having PRP. This further demonstrates the diversity and variation in presentations over time and the diagnostic challenge that this entity poses. The clinical features, forming the basis of the diagnosis of PRP, are varied but well described in the literature. 3, 5 Its highly variable clinical presentation indeed raises the question whether PRP is a single disorder or numerous disorders with a common final pathway. While the influences are likely varied, it seems that it is a single disorder with a multitude of factors leading to varied presentations that progress to a more uniform, final appearance of exfoliative erythroderma in most cases. We demonstrated 2 peaks of onset: one during the first decade of life and a second one in the sixth and seventh decades of life. This has similarities with previously reported peaks of onset of the disease. 3, 8, 10 It also seems that the patients progress to "full bloom" (both clinically and histopathologically) at different rates, which results in variable timing required to obtain the correct diagnosis (eg, with repeated biopsies and clinical examinations). Further studies aimed at defining the exact timing of the disease progression would be useful to dermatologists to determine the return visit timing in cases with an inconclusive initial diagnosis; this may in turn reduce diagnostic delay and costs associated with this difficult diagnosis.
One of the most striking observations in this study was that only 26% of level 1 patients were correctly diagnosed at initial presentation. Diagnosis was delayed 29 months, on average, with a wide range. This delay may primarily reflect the fact that at early stages, presentation of cutaneous findings can be highly variable. Over time, these signs most often evolve into classic features of PRP, facilitating diagnosis. A similar trend was seen in histopathologic diagnosis: the broad array of findings necessitated numerous follow-up biopsies in most patients to enable establishment of the correct diagnosis. Many times, even findings from follow-up biopsies were inconclusive, necessitating clinicopathologic correlation.
Traditionally, PRP has been suggested to be a selflimiting condition, the symptoms subsiding within a 2-to 3-year time frame. 8 However, at the time of our study, 72% of level 1 patients had persistent clinical findings, which had lasted for 58 months on average with a range up to 300 months. Only 28% of adult plus pediatric patients had entered remission before our study was completed; in these cases, the mean length of skin manifestations was 84 months (range, 4-516 months). These findings clearly suggest that PRP, while in some cases a readily self-limiting condition, can persist well beyond the anticipated 2-to 3-year course in other cases. 11 In fact, the natural history of this seems to be more variable than previously realized. This has obvious implications when counseling newly diagnosed patients. Survey of the patients with PRP in our study revealed a number of comorbidities, some of which, such as dyslipidemia, may not differ from the frequency in general population. An increased incidence of hypothyroidism was found in level 1 patients with PRP (20%) vs the general US population (4.6%). 12 In this context, several case studies have previously Abbreviations: NA, not applicable; PRP, pityriasis rubra pilaris. a Subjective, patient-reported "helpfulness." Percentages were calculated as a fraction of those who had tried this therapy. Patients were asked as to whether the specific therapy listed was "helpful;" while most patients appeared to have understood the question as pertaining to the improvement of their signs and symptoms of PRP, survey notes indicated that certain patients considered their treatment "not helpful" because it was too time consuming, had too many adverse effects, and so on.
